AUPH Aurinia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUPH

Price (delayed)

$10.31

Market cap

$1.47B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$1.38B

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The ...

Highlights
The revenue has soared by 194% YoY and by 3.9% from the previous quarter
Aurinia Pharmaceuticals's gross profit has soared by 188% YoY and by 3.3% from the previous quarter
The quick ratio has declined by 26% year-on-year and by 13% since the previous quarter
AUPH's equity is down by 15% year-on-year and by 4.2% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.auriniapharma.com
Peers: QURE LXRX

Key stats

What are the main financial stats of AUPH
Market
Shares outstanding
142.58M
Market cap
$1.47B
Enterprise value
$1.38B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.61
Price to sales (P/S)
10.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.33
Earnings
Revenue
$134.03M
EBIT
-$106.35M
EBITDA
-$103.65M
Free cash flow
-$79.82M
Per share
EPS
-$0.76
Free cash flow per share
-$0.56
Book value per share
$2.85
Revenue per share
$0.94
TBVPS
$3.27
Balance sheet
Total assets
$470.86M
Total liabilities
$65.43M
Debt
$8.09M
Equity
$405.44M
Working capital
$396.43M
Liquidity
Debt to equity
0.02
Current ratio
9.6
Quick ratio
8.74
Net debt/EBITDA
0.83
Margins
EBITDA margin
-77.3%
Gross margin
95.8%
Net margin
-80.7%
Operating margin
-83.2%
Efficiency
Return on assets
-22.2%
Return on equity
-25.4%
Return on invested capital
-31.9%
Return on capital employed
-25%
Return on sales
-79.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AUPH stock price

How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
10.98%
1 week
8.41%
1 month
25.89%
1 year
-19.45%
YTD
138.66%
QTD
138.66%

Financial performance

How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$134.03M
Gross profit
$128.37M
Operating income
-$111.47M
Net income
-$108.18M
Gross margin
95.8%
Net margin
-80.7%
The revenue has soared by 194% YoY and by 3.9% from the previous quarter
Aurinia Pharmaceuticals's gross profit has soared by 188% YoY and by 3.3% from the previous quarter
Aurinia Pharmaceuticals's net margin has surged by 80% YoY and by 10% QoQ
The operating margin has soared by 79% YoY and by 8% from the previous quarter

Growth

What is Aurinia Pharmaceuticals's growth rate over time

Valuation

What is Aurinia Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.61
P/S
10.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.33
Aurinia Pharmaceuticals's EPS has increased by 46% YoY and by 8% QoQ
The price to book (P/B) is 29% higher than the last 4 quarters average of 2.8 but 23% lower than the 5-year quarterly average of 4.7
AUPH's equity is down by 15% year-on-year and by 4.2% since the previous quarter
The revenue has soared by 194% YoY and by 3.9% from the previous quarter
The stock's P/S is 100% less than its 5-year quarterly average of 2200.4 and 21% less than its last 4 quarters average of 13.9

Efficiency

How efficient is Aurinia Pharmaceuticals business performance
Aurinia Pharmaceuticals's return on sales has surged by 80% YoY and by 10% QoQ
AUPH's ROIC has soared by 55% year-on-year and by 11% since the previous quarter
The ROE has increased by 48% YoY and by 2.3% from the previous quarter
The company's return on assets rose by 48% YoY and by 3.1% QoQ

Dividends

What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUPH.

Financial health

How did Aurinia Pharmaceuticals financials performed over time
The quick ratio has declined by 26% year-on-year and by 13% since the previous quarter
Aurinia Pharmaceuticals's current ratio has decreased by 24% YoY and by 13% from the previous quarter
Aurinia Pharmaceuticals's debt is 98% lower than its equity
AUPH's equity is down by 15% year-on-year and by 4.2% since the previous quarter
Aurinia Pharmaceuticals's debt has decreased by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.